Enclomiphene

Phase 3Small molecule

RRepros Therapeutics Inc.

Enclomiphene is one of 57 small molecule programs targeting Hypogonadism. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypogonadismActive, not recruiting

Hypogonadotropic HypogonadismActive, not recruiting

Male InfertilityActive, not recruiting

HypogonadismPhase 3

Active, not recruiting

Hypogonadotropic HypogonadismPhase 2

Active, not recruiting

Male InfertilityPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

48 competitors in Hypogonadism

#DrugCompanyPhaseTrials

Estrace

Novo Nordisk

Approved

1 2

Victoza

Novo Nordisk

Approved

1 3

Andriol

AAuxilium

Approved

6 4

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Approved

5 5

Trelstar

OOncoVerity, Inc.

Approved

1 6

Arimidex

IIstituto Clinico Humanitas

Approved

1 7

Delatestryl

AAntares Pharma Inc.

Approved

1 8

Human Chorionic Gonadotropin

Merck & Co.

Approved

1 9

Clomid

Avodart

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hypogonadism2 trials

Assessment of the Effects of Enclomiphene Citrate on Bone Mineral Density in Men With Secondary Hypogonadism

Completed·RRepros Therapeutics Inc.·Phase 3·NCT01619683·300 enrolled

Phase III Study to Evaluate Morning Testosterone Normalization in Overweight Men With Secondary Hypogonadism

Completed·RRepros Therapeutics Inc.·Phase 3·NCT01739595·181 enrolled

Male Infertility1 trial

Androxal in Male Infertility

Withdrawn·—·Phase 2/3·NCT02160704

Hypogonadotropic Hypogonadism1 trial

A Multi-Center Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Body Composition and Metabolic Parameters With Diet and Exercise in Conjunction With Treatment With 12.5 mg or 25 mg Enclomiphene

Completed·RRepros Therapeutics Inc.·Phase 2·NCT02651688·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Enclomiphene. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Enclomiphene compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Enclomiphene. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Repros Therapeutics Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: RRepros Therapeutics Inc.

Enclomiphene

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hypogonadism2 trials

Male Infertility1 trial

Hypogonadotropic Hypogonadism1 trial

References

Drug Info

Quick Facts

Related News